AMPLIA THERAPEUTICS LIMITED (ATX) - Revolutionizing Cancer and Fibrosis Treatment: CEO Dr. Chris Burns on Groundbreaking FAK Inhibitors and Promising Clinical Trials

ASX BRIEFS

Send us a text

What if you could revolutionize the treatment of cancer and fibrosis with a simple pill? Join us as we sit down with Dr. Chris Burns, CEO and Managing Director of Amplia Therapeutics Limited, to explore how their groundbreaking small molecule inhibitors are poised to change the medical landscape. Chris takes us behind the scenes of their innovative work targeting focal adhesion kinase (FAK), a protein overexpressed in many solid tumors and fibrotic diseases. Learn why Amplia's orally-administered FAK inhibitors stand out in terms of potency, tolerability, and selectivity, and how they offer new hope for patients battling pancreatic cancer and pulmonary fibrosis.
Chris also shares exciting updates on Amplia's Phase 2a ACCENT trial, which is testing their lead agent, Narmafotinib, in combination with standard chemotherapy. With recruitment completed for the first 26 patients and three confirmed partial responses already reported, the trial's early results are promising. Listen in to understand the significance of these milestones and what they mean for the future of Amplia’s drug development. This episode offers a comprehensive look at the potential impact of Amplia Therapeutics' innovative treatments on cancer and fibrosis therapies.